Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Over a 3-year follow-up, the SURMOUNT-1 trial found that treatment with tirzepatide (a dual GLP1/GIP agonist) of patients with obesity and prediabetes led to substantial and sustained weight reduction, with a lower risk of progression to type 2 diabetes
[DOI] [PMC free article] [PubMed] [Google Scholar] 227.Cornelli U
In a single-dose study with the GLP-1 RA exenatide, premedication with oral antiemetics metoclopramide and ondansetron hydrochloride significantly reduced the incidence of nausea and vomiting
Maximum dose: 4 grams daily
When generalizing the results of the case-control study the low participation rate among the controls should be considered
US$ 25.05
US$ 23.50
US$ 26.92
US$ 24.30
US$ 27.11
US$ 20.62
US$ 24.65
US$ 29.13
US$ 27.94
US$ 23.58
US$ 24.40
US$ 27.34
